EXHIBIT 10.5
[*] indicates that a confidential portion of the text of this agreement has been
omitted and filed separately with the Securities and Exchange Commission
AMENDMENT
TO
COLLABORATION AGREEMENT
April 14, 1999
This Amendment is made and entered into as of the date first
written above by and between Genentech, Inc., a Delaware corporation having its
principal executive office at 1 DNA Way, South San Francisco, California 94080
("Genentech"), and XOMA Ltd., a Bermuda company having its principal office at
2910 Seventh Street, Berkeley, California 94710 ("XOMA"), to amend that certain
Collaboration Agreement, dated as of April 22, 1996 (the "Collaboration
Agreement"), by and between Genentech and XOMA.
Genentech and XOMA agree to amend the Collaboration Agreement
as follows:
1. To delete the fourth sentence of Section 5.1(b) in its
entirely.
2. To delete from the last paragraph of Section 5.1(b) the
words "within thirty (30) days after the successful completion of a Phase II
Clinical Trial for one of the Initial Indications" and replace them with the
words "by April 15, 1999".
3. To insert into the second sentence of Section 7.2 an open
parenthesis after the words "set forth in Section 5.1(a)" and before the words
"or Genentech selects", and a closed parenthesis followed by "or 5.1(b)" after
the words "under Section 5.2(c)(2)" and before the comma and the words
"Genentech will loan", and to add to the end of the sentence the clause
"provided that the amount so loaned to XOMA pursuant to this sentence shall not
exceed $[*] million in the aggregate without the prior approval of Genentech's
Board of Directors, which approval Genentech management will seek in good faith
upon the request of the Project Core Team", such that the sentence reads in its
entirety as follows:
"In addition, if XOMA selects the option set forth in Section
5.1(a) (or Genentech selects such option for XOMA under
Section 5.2(c)(2)) or 5.1(b), Genentech will loan XOMA the
amount necessary to fund its development obligations under the
Development Plan based on the annual budget in a similar
fashion each year until the receipt of Regulatory Approval
(unless Genentech earlier terminates this Agreement) under the
terms and conditions of the Note Purchase Agreement, provided
that the amount so loaned to XOMA pursuant to this sentence
shall not exceed $[*] million in the aggregate without the
prior approval of Genentech's Board of Directors, which
approval Genentech management will seek in good faith upon the
request of the Project Core Team."
4. To replace the notice provisions with respect to Genentech
and XOMA in Section 18.8 in their entirety with the following:
-2-
"If to Genentech, addressed to:
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080-4990
Attention: Corporate Secretary
Telephone: (650) 225-1000
Facsimile: (650) 952-9881
If to XOMA, addressed to:
XOMA Ltd.
2910 Seventh Street
Berkeley, CA 94710
Attention: Corporate Secretary
Telephone: (510) 644-1170
Telecopy: (510) 649-7571
With a copy to: C.L. Dellio"
5. To replace all references to "XOMA Corporation" with
references to "XOMA Ltd.", which is a Bermuda company that is the successor in
interest to XOMA Corporation, a Delaware company.
6. To replace all references to "Series E Preferred Stock"
with references to "Series B Preference Shares."
7. To replace all references to "Common Stock" with references
to "Common Shares."
All other terms and conditions of the Agreement shall remain
unchanged by this Amendment.
This Collaboration Agreement may be executed in two
counterparts, each of which will be deemed an original, but both of which
together will constitute one and the same instrument.
[signature page follows]
-3-
IN WITNESS WHEREOF, this Collaboration Agreement has been
executed and delivered on the date first written above by duly authorized
representatives of the parties hereto.
GENENTECH INC. XOMA LTD.
By: /s/ Louis J. Lavigne, Jr. By: /s/ Christopher J. Margolin
---------------------------- -------------------------------
Name: Louis J. Lavigne, Jr. Name: Christopher J. Margolin
Title: Executive Vice President and Title: Vice President,
Chief Financial Officer General Counsel
and Secretary